Aug. 17. 2020
Osaka, Japan - August 17, 2020 - Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 4 generic drugs with 13 strengths. The 2 compounds marked with an asterisk below are approved for the first time as generics.
The list of approved products
1. Pregabalin OD Tablets, Capsules
| Generic name | Pregabalin* |
|---|---|
| Strengths | OD Tablets, Capsules: 25 mg, 75 mg, 150 mg |
| Brand products | Lyrica® OD Tablets 25 mg, 75 mg, 150 mg, Lyrica® Capsules 25 mg, 75 mg, 150 mg |
2. Rivastigmine Tapes
| Generic name | Rivastigmine* |
|---|---|
| Strengths | 4.5 mg, 9 mg, 13.5 mg, 18 mg |
| Brand products | EXELON® PATCH 4.5 mg, 9 mg, 13.5 mg, 18 mg, RIVASTACH® Patches 4.5 mg, 9 mg, 13.5 mg, 18 mg |
3. Bortezomib for Injection
| Generic name | Bortezomib |
|---|---|
| Strengths | 3 mg |
| Brand products | VELCADE® Injection 3 mg |
4. Famotidine Intravenous Injection
| Generic name | Famotidine |
|---|---|
| Strengths | 10 mg, 20 mg |
| Brand products | Gaster® Injection 10 mg, 20 mg |
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.